Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

Hundreds of HIV doctors and researchers have called on the Trump administration to reverse its sweeping aid funding cuts, ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

A patient told MassLive she was horrified to receive a phone call from her surgeon post-operation saying she should be tested for bloodborne pathogens.

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...